| Dr Alit Jeannie Amit-yousif, MD | |
|
18101 Oakwood Blvd, Dearborn, MI 48124-4089 | |
| (313) 436-2583 | |
| (313) 436-2809 |
| Full Name | Dr Alit Jeannie Amit-yousif |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 20 Years |
| Location | 18101 Oakwood Blvd, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538351226 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301084270 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Barbara Ann Karmanos Cancer Institute | 3870407901 | 39 |
| Oakland Macomb Obstetrics And Gynecology, P.c. | 4183673015 | 19 |
News Archive
The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
It's no accident that researchers at the University of Wisconsin-Madison have taken a lead role addressing the Zika virus epidemic gripping the Americas. Many of them were already at work fighting viruses and mosquito-borne diseases in Central and South America.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
› Verified 1 days ago
| Entity Name | Barbara Ann Karmanos Cancer Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225022288 PECOS PAC ID: 3870407901 Enrollment ID: O20031113000601 |
News Archive
The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
It's no accident that researchers at the University of Wisconsin-Madison have taken a lead role addressing the Zika virus epidemic gripping the Americas. Many of them were already at work fighting viruses and mosquito-borne diseases in Central and South America.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
› Verified 1 days ago
| Entity Name | Oakland Macomb Obstetrics & Gynecology, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760424139 PECOS PAC ID: 4183673015 Enrollment ID: O20050119000049 |
News Archive
The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
It's no accident that researchers at the University of Wisconsin-Madison have taken a lead role addressing the Zika virus epidemic gripping the Americas. Many of them were already at work fighting viruses and mosquito-borne diseases in Central and South America.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alit Jeannie Amit-yousif, MD 14180 Sherwood St, Oak Park, MI 48237-1384 Ph: (313) 436-2583 | Dr Alit Jeannie Amit-yousif, MD 18101 Oakwood Blvd, Dearborn, MI 48124-4089 Ph: (313) 436-2583 |
News Archive
The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
It's no accident that researchers at the University of Wisconsin-Madison have taken a lead role addressing the Zika virus epidemic gripping the Americas. Many of them were already at work fighting viruses and mosquito-borne diseases in Central and South America.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
› Verified 1 days ago
Frankju A Arevalo, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 840 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-359-7650 Fax: 313-359-7660 | |
Dr. Rohan Lalith Deraniyagala, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 248-551-5490 | |
Jerry W Drake, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 840 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-359-7650 Fax: 313-359-7660 | |
Hassan Hamadi, DO Radiology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Joon K Kim, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 840 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-359-7650 Fax: 313-359-7660 | |
Jeffery Michael Holton, MD Radiology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Gme Office, Dearborn, MI 48124 Phone: 313-593-7000 | |
Dr. Michael Walter Ramalia Jr., DO Radiology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 |